pingmei coal(SH:601666) Shang Hai Zheng Quan Bao·2025-09-25 23:17Market Updates - The Shanghai and Shenzhen stock exchanges announced the holiday trading schedule for the National Day and Mid-Autumn Festival, with a market closure from October 1 to October 8, resuming on October 9 [2] - The China Foreign Exchange Trading Center announced the optimization of the "Swap Connect" mechanism under the guidance of the People's Bank of China, including a dynamic adjustment mechanism for quote providers and an increase in the daily net limit to 45 billion yuan starting October 13, 2025 [2] - The fourth Global Digital Trade Expo signed 45 major projects with a total investment of 64.87 billion yuan (including 300 million USD), focusing on digital economy and artificial intelligence [2] Industry Insights - The China Nonferrous Metals Industry Association's Copper Industry Branch expressed strong opposition to "involution" competition in the copper smelting industry, which has led to persistently low processing fees for copper concentrate [4] - Tianfeng Securities emphasized that the key to "anti-involution" in the copper smelting industry lies in optimizing capacity, including phasing out outdated capacity and enhancing efficiency through advanced smelting technologies [5] Company Announcements - Pingmei Shenma Group notified Pingmei Co. that the Henan Provincial Government decided to implement a strategic restructuring of Henan Energy Group and Pingmei Shenma Group [9] - China Railway recently won multiple major engineering contracts totaling approximately 50.215 billion yuan, accounting for about 4.34% of the company's projected revenue for 2024 [10] - China Oil Engineering announced that its subsidiary signed an EPC contract worth 2.524 billion USD (approximately 18.032 billion yuan) for a seawater pipeline project in Iraq [11] - Baili Tianheng's drug Iza-bren has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with seven indications already recognized [12] - New Nuo Wei's drug for Alzheimer's disease has received approval for clinical trials, marking a significant milestone in the development of biosimilars in China [13] - Jihong Co. expects a net profit of 257 million to 270 million yuan for the first three quarters of 2025, representing a year-on-year increase of 95.07% to 105.31% [14] Institutional Activity - Four institutional seats purchased a total of 106 million yuan in Heng Erda, which represents 12.1% of the total trading volume [15] - One institutional seat bought 134 million yuan in Inspur Information, accounting for 1.3% of the total trading volume [16]